Alle Studien
Aktiv, aber nicht rekrutierendPHASE3INTERVENTIONELL

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

This research is testing a medicine called migalastat for people living with Fabry disease. It's specifically for those whose Fabry disease is linked to certain genetic changes that migalastat can help, and who also have significant kidney problems. The study will look at two groups: one with severe kidney damage who are not on dialysis, and another group who are already receiving dialysis treatment. The main goals are to understand how safe migalastat is and how the body processes it in these situations. This is an 'open-label' study, meaning both patients and doctors will know they are receiving migalastat. It's an important step to gather more information about using this treatment in people with advanced kidney disease tied to Fabry disease.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE3
Sponsor
Amicus Therapeutics
Einschreibeziel
14
Starten
31. Okt 2022
Geschätzte Fertigstellung
31 Dez 2026

Worum geht es in dieser Studie?

This study is about a medicine called migalastat, used for a rare genetic condition called Fabry disease. Fabry disease can cause lots of health problems, including serious damage to the kidneys. This study is specifically for people with Fabry disease who have certain genetic changes that migalastat is known to work for, and who also have severe kidney problems.

We want to find out more about how safe migalastat is and how the body handles it in people whose kidneys are severely affected. This includes people with very advanced kidney disease who are not yet on dialysis, and also those who are already receiving dialysis treatment. We hope this study will give us valuable information to help doctors best support people with Fabry disease and kidney issues.

It's important to understand that this is an 'open-label' study. This means everyone involved – the patients and the doctors – will know that migalastat is being given. There isn't a comparison group receiving a dummy pill or a different medicine in this particular study.

Wichtige Erkenntnisse

  • This study is for adults with a specific type of Fabry disease and severe kidney problems.
  • It tests a medicine called migalastat to check its safety and how it works in people with kidney damage or on dialysis.
  • Participation involves taking migalastat and having regular check-ups.
  • You cannot join if you've had a kidney transplant or are on peritoneal dialysis.
  • This is an 'open-label' study, so everyone knows you're receiving migalastat.

Wer könnte berechtigt sein?

To join this study, you need to be an adult (18 years or older) with a diagnosis of Fabry disease. Your doctors must have noted that your specific type of Fabry disease, based on your genetic test results, is one that migalastat can help. You also need to have severe kidney problems, meaning your kidney function is quite low, as measured by a specific kidney test within the last three months and again at the start of the study.

If you have very severe kidney disease and are on dialysis, you might still be able to join. However, you would need to be on a regular dialysis schedule (2 or 3 times a week) for at least two months before starting the study. It's also important that you can receive your dialysis sessions at the study clinic or a nearby centre that the study doctor works with, and that you commit to completing all your prescribed dialysis sessions.

Unfortunately, you can't join if you've already had a kidney transplant, or if you're on a different type of dialysis called peritoneal dialysis. You also can't be taking other experimental drugs, or certain specific Fabry disease medications. If you've had certain heart problems recently, or have serious unstable heart or other medical conditions, or a history of allergic reactions to migalastat or similar drugs, you wouldn't be able to take part.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you 18 years or older with Fabry disease?
  2. Has your doctor confirmed your Fabry disease type can be treated with migalastat?
  3. Do you have severe kidney problems (eGFR below 30)?
  4. If on dialysis, are you on hemodialysis 2-3 times a week for at least 2 months?
  5. Have you NOT had a kidney transplant or been on peritoneal dialysis?
  6. Are you NOT taking other study drugs or certain Fabry medications currently?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, your first step will be a screening visit to check if you're suitable for the study. This will likely involve confirming your Fabry disease type and your kidney function. If you meet all the requirements, you'll have a main starting visit within a month. During this study, you'll be taking migalastat as prescribed.

For those on dialysis, special arrangements will be made to ensure your dialysis sessions can happen at the study clinic or an affiliated centre, and you'll need to commit to attending all your scheduled dialysis sessions. The study will involve regular check-ups and assessments to monitor your health, how the medicine is working, and to ensure your safety. The total duration of your participation will be explained to you during the consent process.

Potenzielle Risiken und Vorteile

Participating in this study might offer a potential benefit by giving you access to migalastat, which could help manage your Fabry disease, especially if you have significant kidney involvement. However, like all medicines, migalastat can have side effects, and some tests or procedures during the study might have their own small risks. The study team will carefully monitor your health throughout. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Standorte (12)

  • Emory University
    Verifizierte Postleitzahl
    Atlanta, Vereinigte Staaten
  • The Cleveland Clinic
    Verifizierte Postleitzahl
    Cleveland, Vereinigte Staaten
  • Lysosomal and Rare Disorders Research and Treatment Center, Inc
    Verifizierte Postleitzahl
    Fairfax, Vereinigte Staaten
  • Royal Melbourne Hospital
    Verifizierte Postleitzahl
    Parkville, Australien
  • Royal Perth Hospital
    Verifizierte Postleitzahl
    Perth, Australien
  • Osaka University Hospital
    Verifizierte Postleitzahl
    Suita, Japan
  • Shizuoka General Hospital
    Verifizierte Postleitzahl
    Shizuoka, Japan
  • Centro Hospitalar e Universitário de Coimbra (CHUC)
    Verifizierte Postleitzahl
    Coimbra, Portugal
  • Hospital Universitari(o) de Bellvitge (HUB) Feixa Llarga
    Verifizierte Postleitzahl
    Barcelona, Spanien
  • Hospital General Universitario de Elda
    Verifizierte Postleitzahl
    Elda, Spain
  • Hospital General Universitario Gregorio Marañon
    Verifizierte Postleitzahl
    Madrid, Spanien
  • Salford Royal Hospital
    Verifizierte Postleitzahl
    Salford, United Kingdom

Häufige Fragen

What is Fabry disease?

Fabry disease is a rare inherited condition that can affect many parts of the body, including the kidneys, heart, and skin, because the body can't break down a certain type of fat properly.

What is migalastat?

Migalastat is a medication used to treat certain types of Fabry disease where the specific genetic change allows the drug to help the body's own enzymes work better.

Why is this study only for people with kidney problems?

This study is specifically looking at how migalastat works and its safety in people with Fabry disease who also have severe kidney damage, including those on dialysis, as there's less information about how the drug behaves in these situations.

What does 'open-label' mean?

Open-label means that everyone involved in the study – both the patient and the doctors – will know that the patient is receiving the study medication, migalastat.

Muss ich bezahlen, um an der Studie teilzunehmen?

No, you will not have to pay for the study medication or any study-related tests and appointments. Travel costs may also be reimbursed.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.